Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Zutphen – page 4

842 clinical trials in Zutphen, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Zutphen at a glance
842
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

842 trials in Zutphen

Open in trial search
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Napazimone
  • Sponsor:Pharming Technologies B.V.

Study of ELA026 for Treatment of Secondary Hemophagocytic Lymphohistiocytosis in Patients with Lymphoma Who Have Not Received Previous Treatment

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ELA026
  • Sponsor:Electra Therapeutics Inc.

Study on Golcadomide for Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Brain

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Prostate cancer

Recruiting

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:Novartis Pharma AG

Study Comparing Clindamycin to Rifampicin and Drug Combination for Patients with Prosthetic Joint Infection

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Clindamycin
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study on Early Diffuse Cutaneous Systemic Sclerosis: Comparing Stem Cell Transplantation with Cyclophosphamide, Filgrastim, and Mycophenolate Mofetil

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Filgrastim
  • Sponsor:Universitair Medisch Centrum Utrecht

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

A Phase II Randomized, Double‑Blind Study of RO7568282 for Safety and Efficacy in Early‑Stage Parkinson’s Disease Patients

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Zutphen

What the registry says about research in the country

01 Respiratory Diseases

Clinical research focusing on respiratory conditions including innovative treatments for asthma and viral infections. Studies encompass evaluation of new vaccine combinations and safety assessments of inhalation devices.

  • RSV and COVID-19 vaccine co-administration
  • Moderate to severe asthma treatments
  • Chronic Obstructive Pulmonary Disease management
  • Bronchiectasis therapy

Investigations include both preventive measures and therapeutic interventions for respiratory conditions.

02 Cardiovascular Studies

Comprehensive research into cardiovascular health, examining treatments for various heart conditions and prevention of major cardiac events.

  • Atherosclerotic Cardiovascular Disease
  • Heart Failure Management
  • Post-Heart Attack Treatment
  • Acute Coronary Syndrome

Focus on innovative therapies and interventions to improve patient outcomes in heart-related conditions.

03 Oncology Research

Advanced studies in lung cancer treatment and innovative therapeutic approaches for various cancer types.

  • Non-Small Cell Lung Cancer therapies
  • Immunotherapy optimization
  • Mantle Cell Lymphoma treatment

Evaluating novel treatment combinations and immunotherapy approaches for better patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.